Centene Corp : Truist Securities Raises Target Price to $80 from $78

Analysts Offer Insights on Healthcare Companies: Kuros Biosciences (OtherCSBTF), Centene (CNC) and Incyte (INCY)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Centene (CNC) and Dyne Therapeutics (DYN)

Centene Director Paul J. Diaz Files Initial Beneficial Ownership Statement

Centene Falls After Flagging Bigger Drop in Medicaid Membership

NASDAQ Trade Halt Volatility Trading Pause at 09:31 Am

Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Tuesday

Centene CEO Says Co is Expecting Lower Year-End Membership than Its Previous Outlook Through the Back Half of the Year - Conf. Call

U.S. Stocks on the MOVE-Sherwin-Williams, Johnson & Johnson, IQVIA

Centene Corp Reports Results for the Quarter Ended June 30 - Earnings Summary

Centene Commercial Profitability Surges on Marketplace Pricing Realignment

Centene's Medicare and Commercial Windfalls Drive Annual Guidance Increase

Centene Corp: on July 27, 2026, Committed to Accept Employees' Offers to Participate in a Voluntary Separation Program

Centene: Estimates Severance Costs of $315m-$365m for Voluntary Separation Program in 2026 - SEC Filing

Centene Shares Rise 3.7% Premarket After Co Lifts Annual Profit Forecast

Centene Appoints Cressey’s Paul Diaz to Board as Burdick Retires

Centene Q2 FY26 GAAP Diluted EPS Swings to Profit at $2.19; Revenue Rises 9.92% to $53.58 Billion vs Q2 FY25

Centene Raises Annual Profit Forecast on Better Cost Control

Centene Q2 Adjusted EPS USD 2.51 Vs. IBES Estimate USD 1.08

Centene Announces Board of Directors Changes